News

Article

Clinical Quiz: Systemic JIA Treatment Recommendations from 2021 ACR JIA Guidelines

Test your knowledge of systemic juvenile idiopathic arthritis (JIA) treatment recommendations from the 2021 ACR guideline on JIA with this quiz.

Systemic juvenile idiopathic arthritis (JIA) is considered by some rheumatologists to be an autoinflammatory disorder, with patients experiencing rash, fever, and visceral involvement in addition to the stiff, swollen, and painful joints associated with arthritis. Up to 40% of patients with systemic JIA are also diagnosed with macrophage activation syndrome (MAS), a life-threatening complication that presents with elevated liver enzyme levels, low fibrinogen levels, high triglyceride levels, high ferritin levels, cytopenia, and fevers. Careful monitoring and effective treatment strategies are critical, as this syndrome can occur at any point during the disease course.

In the third installment in a series of clinical quizzes based on the American College of Rheumatology’s 2021 Guideline for the Treatment of Juvenile Idiopathic Arthritis, we focus on treatment recommendations for pediatric patients with systemic JIA, both with and without MAS.

What type of medications are strongly recommended against as initial treatment for systemic JIA without MAS?


Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
4 experts are featured in this series.
4 experts are featured in this series.
Malin Fromme, MD | Credit: RWTH Aachen
Pavel Strnad, MD | Credit: AASLD
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
© 2024 MJH Life Sciences

All rights reserved.